Good morning, everyone. Hope you’re powering through this short week before the holiday and aren’t too distracted by daydreams of your Thanksgiving dessert of choice. This is Rachel Cohrs sitting in today. Our morning cup of stimulation comes in the form of a matcha latte. Here are a few items to help you catch up this Tuesday, and as always, stay in touch. …
Safety concerns are growing over Biogen’s (BIIB) Alzheimer’s drug Aduhelm as a new paper showed brain swelling in 35% of clinical trial patients, Bloomberg tells us. Most people did not experience symptoms, however. The study in JAMA Neurology is one of the first formal publications of data from the company’s final-stage trials of Aduhelm.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
